Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
325
resultados
Última actualización
12/09/2026 [07:30:00]
Resultados 275 a 300 de 325
Resumen de: WO2026150914A1
This pharmaceutical composition for use in the treatment of patients with diseases associated decreased ATP levels comprises the DNA or mRNA of at least one molecule selected from the group consisting of PI3Kα, IGFBP1, EIF2S2, OCIAD2, MANF, and GAPDHS.
Resumen de: WO2026148492A1
Provided are a biological target and associated therapeutic strategies for treating or preventing neurodegenerative diseases characterized by pathological α-synuclein (α-syn) fibril transmission.
Resumen de: WO2026151828A1
Provided are methods of isolating or extracting human mitochondrial tryptophan-rich sensory protein (HsTSPOl). The methods include contacting the H.sTSPOl with an effective amount of at least one Native Cell Membrane Nanoparticle (NCMN) polymer and recovering the TSPO. Compositions containing TPSO encapsulated in a particle formed by the NCNM polymer are also provided. A protoporphyrin derivative compound, methods of producing bilindigin or derivatives thereof, and methods of screening compounds that modulate TSPO activity are also provided.
Resumen de: US20260201026A1
0000 The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and/or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (PDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament.
Resumen de: US20260199318A1
Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasonmal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.
Resumen de: US20260199341A1
The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.
Resumen de: US20260199509A1
Provided herein is a method of treating biliary tract cancers in humans. The method uses an antibody-drug conjugate (ADC) comprising an antibody (or antigen-binding fragment thereof) which specifically binds claudin 18.2 (CLDN18.2). The ADC is used for treatment of biliary tract cancers which express CLDN18.2.
Resumen de: US20260202374A1
The present disclosure provides a method of manufacturing a biosensor for detecting a biomarker of Alzheimer's disease, comprising steps of depositing an aluminum oxide film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing electrical contacts Cr/Au on the Al2O3/Si substrate by a thermal evaporator to form a source, a drain and a planar gate on the Al2O3/Si substrate; providing a bilayer graphene on the Al2O3/Si substrate by thermal annealing under a vacuum environment; providing a bilayer graphene to a low-damage plasma treatment (LDPT) with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite on the Al2O3/Si substrate; and immobilizing an antibody on a surface of the GO/G layered composite through a reaction between amine groups of the antibody and carboxyl groups of GO of the GO/G layered composites, wherein the antibody is specific for p-tau217 protein.
Resumen de: AU2025215582A1
The present disclosure provides, e.g., signature peptide compounds corresponding to various full-length protein components of the complement enzymatic cascade (e.g., C1q, C1s, C3, C3p, C4, C4p, C5, C5p, FB, and FBp). In one aspect, the invention relates to using these signature peptides for measuring and/or monitoring activation of the complement pathway, e.g., in clinical samples, such as plasma, serum, CSF, aqueous humor, or vitreous humor.
Resumen de: AU2024395871A1
The present disclosure provides methods for simultaneously identifying dynamic and disease-associated RNA binding protein (RBP)-RNA interaction (PRI) sites at single nucleotide resolution across the entire transcriptome. The methods disclosed herein recapitulates PRI profiles obtained with several distinct conventional PRI methods in a single assay at efficiencies that are improved by orders of magnitude, and permit the identification of the specific RBP bound at a PRI.
Resumen de: WO2026151876A1
Disclosed herein are embodiments related to analyzing brain-derived extracellular vesicles (EVs). Some methods described herein comprise: (a) enriching a biological sample for brain-derived EVs, the biological sample being from a subject having a brain-related condition or disorder and comprising the brain-derived EVs; (b) subjecting the enriched sample to EV disruption to produce an analytic sample; (c) purifying the analytic sample to capture EV material after the EV disruption; and (d) analyzing the captured EV material to determine a differential amount of the captured EV material relative to a control. The method allows for improving 10 outcomes for patients suffering from brain-related conditions or disorders.
Resumen de: WO2026151932A1
The present disclosure relates to diagnosis, prognosis, and prediction of treatment outcomes of neuropathological conditions.
Resumen de: WO2026151983A1
Aspects of the disclosure relate to compositions and methods for modulating levels, transcription, splicing, and/or translation of one or more RNA transcripts (e.g., mRNA transcripts) in a cell or subject. The disclosure is based, in part, on methods of identifying a subject of having or being at risk of developing a disease or disorder associated with dysregulated glutamine levels, such as a subject having a mutation that affects glutaminase (GLS1), which is an enzyme responsible for producing glutamate from glutamine. In some embodiments, compositions and methods of the disclosure are useful for treating a psychiatric disorder (e.g., depression (DEP), major depressive disorder (MDD), bipolar disorder (e.g., BPD1, BPD2), mania (MAN), psychosis (PSY), schizophrenia (SCZ), schizoaffective disorder (SZA), or post-traumatic stress disorder (PTSD)) and/or a disease associated with dementia, such as Alzheimer's disease.
Resumen de: US20260201015A1
0000 Target-binding polypeptide are disclosed that include an amino acid sequence at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:1-12, nucleic acids encoding such polypeptides, and methods for use of the polypeptides in detecting binding of the target and correlating binding to the target with a disease state.
Resumen de: US20260202406A1
0000 The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of abundance or expression of immune cells, autoantibodies, and/or cytokines.
Resumen de: US20260202422A1
The invention relates to a method of treatment for early onset preeclampsia in a pregnant subject, including determining a level of soluble fms-like tyrosine kinase-1 (sFlt-1) or fragment(s) thereof in a sample that has been isolated from said pregnant subject. The invention further relates to the combined measurement of sFlt-1 and PlGF, The invention relates further to a kit for carrying out the method of the invention, including detection reagents for determining the level sFlt-1 or fragment(s) thereof, and optionally for determining the level of at least one additional biomarker, in a sample from a subject.
Resumen de: US20260201473A1
0000 Biomarkers that can be used for the detection or diagnosis of disease states, preferably cancer (e.g., triple negative breast cancer (TNBC)) disease states, to the prediction of disease prognosis and/or a treatment outcome, to the identification of a treatment regimen for cancer (e.g., TNBC), and/or to indicate the responsiveness to the treatment regimen for cancer (e.g., TNBC) in a subject are described. Also described are probes capable of detecting the biomarkers and related methods and kits for determining cancer (e.g., TNBC) disease states and/or identification of treatment regimens for the cancer (e.g., TNBC) disease states.
Resumen de: US20260201023A1
0000 Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Resumen de: AU2024418168A1
A protein antigen for Alzheimer's disease detection comprises at least any two of DOC2A, LGALS1, KDM4D, and ADARB1 proteins at the same time, can be used for early detection or diagnosis of Alzheimer's disease, and is suitable for risk assessment and prediction of before the onset of Alzheimer's disease; moreover, the protein antigen can distinguish Alzheimer's disease from other types of dementia, and can be further prepared into a related reagent or kit according to requirements.
Resumen de: WO2025014769A1
The present application provides, in some aspects, methods of assaying for β-catenin depots, and uses thereof, such as to identify a compound that modulates, such as increases, the β-catenin depots in a cell. In other aspects, also provided herein are associated methods (such as methods of identifying a compound useful for treating a β-catenin associated disease), kits, and useful compounds identified therefrom.
Resumen de: WO2026151791A1
Provided herein are systems, kits, and methods for cell type-antigen marker (CTA marker) detection in cell samples (e.g., blood or CSF) from those suspected of having pre-clinical AD (Pre-AD) or mild cognitive impairment (MCI) or dementia from Alzheimer's Disease. In certain embodiments, such CTA marker detection is quantitative, gender specific, employs at least two gender-specific CTA markers in Figure 7C, and/or employs a mass cytometer (e.g., where mass-labeled antigen binding agents are mixed with the cell-sample). In some embodiments, at least some of the CTA markers are: i) unhealthy CTA markers which are generally upregulated in subjects with Pre-AD or MCI or dementia from Alzheimer's disease, and/or ii) healthy CTA markers which are generally down regulated in subjects with Pre-AD or MCI or Alzheimer's disease. In particular embodiments, the unhealthy CTA markers, and any healthy CTA markers employed, are used for determining a subject's risk of having or developing Pre-AD or MCI or dementia from Alzheimer's disease (e.g., by generating a score).
Resumen de: WO2026149125A1
Provided are a nanobody against γ-aminobutyric acid type B receptor, and a preparation method therefor and the use thereof. The nanobody can specifically recognize and bind to the γ-aminobutyric acid type B receptor, exhibits a good affinity therefor, and can be used in the preparation of a product for diagnosing, preventing or treating diseases or conditions associated with the γ-aminobutyric acid type B receptor, or for detecting the presence or level of the γ-aminobutyric acid type B receptor in a sample.
Resumen de: US20260202427A1
0000 Described is use of biomarkers found in maternal mid-gestation (MMG) and cord blood (CB) plasma for early identification of children with autism spectrum disorder (ASD) or at risk for ASD. Using these biomarkers, newborns and infants with ASD or at high risk of ASD can be identified and interventions for ASD, which have been shown to be effective early in life, can be provided to a child as young as a newborn.
Resumen de: US20260201041A1
0000 The present invention relates to anti-CD103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases.
Nº publicación: US20260202426A1 16/07/2026
Solicitante:
CHANG JAE WON [KR]
CHANG Jae Won
Resumen de: US20260202426A1
0000 The present disclosure relates to a method of detecting a molecule associated with the diagnosis of a disease through movement of the molecules after fluorescent labeling or by using dynamic X-rays. A method of detecting a molecule associated with the diagnosis of a disease through movement of the molecules after fluorescent labeling or labeling with a crystalline plane, according to an aspect, enables large-scale imaging and Z-axis imaging, and thus can be effectively used in the field of diagnosis.
BOPI
Sede Electrónica
